Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Norbel Baby Co., Ltd (6844.TWO)
Kaohsiung, TW
Norbel Baby Co., Ltd is a Taiwanese company that offers a diverse range of products, encompassing maternity and infant care items, medical provisions, nutritional supplements, and beauty products. Their merchandise is also available for purchase through a network of franchised retail locations. Established in 1986, this firm maintains its headquarters in Kaohsiung, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | -2.85% | +0.78% | +1.57% | -15.65% | -14.76% | -39.81% | -70.79% | -61.72% | -61.72% | -61.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Specialty Retail: +6.4%+1.4% Q1'26: -2.5% (vs Q1'25)
-
EPS growth Specialty Retail: +20.6%-21.7% Q1'26: +18.9% (vs Q1'25)
-
FCF margin FCF growth · Specialty Retail: +29.3%+7.3% Q1'26: +5.6% (vs Q1'25)
-
EBIT margin Specialty Retail: +5.4%+2.2% Q1'26: +2.9% (vs Q1'25)
-
ROIC Specialty Retail: +6.5%+2.5% Q1'26: +3.5% (vs Q1'25)
-
Share dilution Specialty Retail: +0.1%+0.8% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Specialty Retail: 0.14×3.60× ★ Q1'26: 3.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
|---|---|
| Revenue |
3.40B
est: 3.53B (-3.6%)
|
| EBITDA |
393.53M
est: 465.99M (-15.5%)
|
| EBIT |
156.71M
est: 245.98M (-36.3%)
|
| Net Income |
111.58M
est: 221.01M (-49.5%)
|
| SGA |
1.01B
est: 903.93M (+12.2%)
|
| EPS |
3.00
est: 5.90 (-49.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng-Hsing Chang | Chief Pharmacy Officer & Director | — | male |
| Chih-Yung Chang | Director of Sales Division | — | male |
| Hui Qi Fang | Director of Finance & Accounting Department | — | female |
| Wang-Shen Hsu | President & Director | — | female |
| Yao-Hung Hsu | Vice President & Representative of Corporate Director | — | male |
| Zhi Cheng Wu | Head of Corporate Governance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6844.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
